NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 5 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Excel Industries released its Q2 & H1 FY27 earnings conference call transcript, highlighting a 1.6% YoY standalone revenue increase to ₹274.6 Cr and a 21.5% increase in EBITDA to ₹36.6 Cr (margins expanded to 13.3% from 11.1%). The company's diversification into Performance Solutions, Yellow Phosphorus (YP) derivatives, and Contract Manufacturing helped cushion a weak agrochemical demand driven by suboptimal monsoons (87% of normal). Notably, the dedicated facility for its 5-year supply contract was completed on July 23, 2026, and is now supplying at full stream, boosting exports to ₹81 Cr compared to ₹47 Cr in Q2 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the formal transcript of the Q2 & H1 FY27 earnings conference call held on November 6, 2026.
ஏன் இது முக்கியம்Demonstrates that strategic pivots toward specialty non-agro chemicals, biocide expansions, and contract manufacturing are delivering margin resilience despite a deep cyclical downturn in domestic agrochemicals.
📅 குறுகிய காலம்Agrochemical demand is guided to remain subdued through Q3 FY27 due to weak monsoon effects, but operational efficiencies and new contract volumes will support base profitability.
📈 நீண்ட காலம்Successful commercialization of long-term contract manufacturing and non-agro specialty chemicals (YP derivatives, biocides) structurally lowers exposure to volatile agrochemical cycles.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility and shipping disruptions creating cost pressure in H2
Continued softness in the core agrochemical segment
👀 கவனிக்க வேண்டியவை
Track the ramp-up of the long-term contract supplies in H2 FY27 and watch for planned launches in the Performance Solutions segment in Q3 and YP derivatives in Q4.
Excel Industries Q2 FY27: PAT Up 42% YoY to ₹27 Cr Despite Weak Agrochemical Demand
Excel Industries released its Q2 & H1 FY27 investor presentation showing a 42% YoY jump in standalone PAT to ₹27 Cr and a 22% increase in EBITDA to ₹37 Cr, despite revenue rising just 2% YoY to ₹275 Cr. Performance was supported by diversification into Performance Solutions, Contract Manufacturing, and YP Derivatives, which offset the lowest DETC agrochemical intermediate sales in 11 years. Q2 exports grew significantly to ₹81 Cr from ₹47 Cr in the prior year, aiding EBITDA margin expansion by 220 bps to 13.3%. Management cautioned that agrochemical demand is expected to remain soft in Q3, with raw material price volatility persisting.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the detailed Q2 & H1 FY27 investor presentation detailing operational performance and segment outlook.
ஏன் இது முக்கியம்Demonstrates resilience and margin expansion from non-agro chemical diversification, contract manufacturing, and export growth during a cyclical downturn in core agrochemical intermediates.
📅 குறுகிய காலம்Margin improvement and strong export growth are positive indicators, though soft guidance for Q3 agrochemical demand may cap near-term top-line acceleration.
📈 நீண்ட காலம்Continued strategic pivot towards non-agro specialty chemicals, contract manufacturing, and biocide expansions should structurally reduce reliance on cyclical agrochemical demand.
⚠ அபாய எச்சரிக்கைகள்
Agrochemical intermediate demand (DETC) remains weak heading into Q3
Raw material price volatility and shipping disruptions continue to present margin risks
👀 கவனிக்க வேண்டியவை
Track agrochemical sector recovery and the progress of new Performance Solutions product launches expected in Q3 FY27, along with raw material cost trends.
Excel Industries Q2 FY27 PAT Rises 42.4% YoY to ₹26.67 Cr; Revenue at ₹274.61 Cr
Excel Industries reported standalone revenue from operations of ₹274.61 Cr for Q2 FY27 (quarter ended September 30, 2026), up 1.6% YoY from ₹270.19 Cr in Q2 FY26, but declining 6.5% QoQ from ₹293.73 Cr. Standalone net profit for the quarter grew 42.4% YoY to ₹26.67 Cr compared to ₹18.73 Cr in Q2 FY26, supported by lower raw material consumption costs. For H1 FY27, revenue stood at ₹568.34 Cr against ₹579.66 Cr in H1 FY26, while net profit improved 6.7% YoY to ₹55.78 Cr. Basic and diluted EPS for the quarter came in at ₹21.21 compared to ₹14.90 in the year-ago period.
உச்சம் நம்பிக்கை
என்ன மாறியதுExcel Industries reported its Q2 and H1 FY27 financial results showing a 42.4% YoY jump in quarterly net profit despite modest revenue growth.
ஏன் இது முக்கியம்Higher profit margins and reduced raw material costs bolstered quarterly bottom-line performance, tracking ahead of the previous year's quarterly run rate despite sequential revenue moderation.
Q2 FY27 Revenue from Operations: ₹27,461.47 லட்சம்Q2 FY27 Profit After Tax: ₹2,667.41 லட்சம்Q2 FY27 EPS: ₹21.21H1 FY27 Profit After Tax: ₹5,578.16 லட்சம்Net cash outflow from operations (H1 FY27): ₹(6,342.90) lakhs
📅 குறுகிய காலம்Market may react positively to the strong 42% YoY profit growth and margin expansion, though sequential revenue softening from Q1 FY27 will be noted.
📈 நீண்ட காலம்Performance will hinge on diversifying away from seasonal agrochemical exposure into specialty chemicals, biocides, and stabilizing working capital flows.
⚠ அபாய எச்சரிக்கைகள்
Negative operating cash flow in H1 FY27 of ₹(63.43) Cr largely due to working capital expansion and inventory buildup.
Seasonal and cyclical sensitivity inherent to the agrochemicals sector.
👀 கவனிக்க வேண்டியவை
Track whether margin expansion can sustain in upcoming quarters amid agrochemical cyclicality and progress on the non-agro specialty chemicals contract investment.
Excel Industries AGM Approves Rs 13.75 Per Share Dividend (275%)
Excel Industries Limited held its Annual General Meeting on September 24, 2026, where shareholders approved all proposed resolutions with requisite majority. Key approvals include the adoption of FY26 financial statements and a final dividend of Rs 13.75 per equity share (275% on face value). Additionally, shareholders approved the re-appointment of Director Hrishit Shroff, executive director remuneration, and cost auditor remuneration. A total of 52 shareholders attended via video conferencing out of 22,328 shareholders as of the record date.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal shareholder ratification of FY26 financial statements and confirmation of the Rs 13.75 per share final dividend.
ஏன் இது முக்கியம்Confirms the cash distribution to shareholders, maintaining shareholder returns from FY26 profits on a largely debt-free balance sheet.
Final dividend per share: Rs. 13.75Dividend percentage: 275%Total shareholders on record date: 22328AGM date: 24th செப்டம்பர், 2026
📅 குறுகிய காலம்Neutral to mildly positive as dividend disbursement proceeds; minimal immediate stock price impact expected given this is a scheduled approval.
📈 நீண்ட காலம்Limited; reflects routine corporate governance and steady capital allocation consistency.
👀 கவனிக்க வேண்டியவை
Track the dividend payout timeline and watch for upcoming Q2 FY27 results to monitor revenue performance in non-agro specialty chemicals.
Excel Industries Q1 PAT Drops 13% YoY to ₹29.1 Cr; Completes ₹40 Cr Dedicated Facility
In its Q1 FY27 investor presentation, Excel Industries reported standalone revenue of ₹293.7 crore (down 5.1% YoY) and PAT of ₹29.1 crore (down 13.3% YoY), impacted by erratic monsoon demand in agrochemical intermediates and lower other income. Operating EBITDA remained steady at ₹42.4 crore, with margins expanding 70 bps YoY to 14.4% driven by improved product mix. The company successfully commissioned its ₹40 crore dedicated manufacturing project on July 23, 2026, which backs a 5-year supply agreement with ₹35-40 crore annual revenue potential. Furthermore, a 1,265 MTPA specialty chemical expansion at Lote (₹5 crore capex) is slated for commissioning by February 2027.
உச்சம் நம்பிக்கை
என்ன மாறியதுReleased Q1 FY27 earnings presentation and announced the on-time commissioning of a ₹40 crore dedicated contract manufacturing facility.
ஏன் இது முக்கியம்The completed facility adds ~₹35-40 crore in high-margin non-agro revenue (~3.5% of TTM revenue), aiding strategic diversification away from monsoon-dependent agrochemicals.
📅 குறுகிய காலம்Agrochemical intermediate demand remains soft in Q2 FY27, though incremental revenue from the new dedicated plant will begin supporting top-line figures.
📈 நீண்ட காலம்Expansion into non-agro specialty chemicals, biocide platforms, and long-term contract manufacturing gradually reduces dependence on cyclical crop cycles.
⚠ அபாய எச்சரிக்கைகள்
Near-term demand headwinds in the agrochemical intermediates segment.
Raw material price volatility and ongoing global shipping/logistics disruptions.
👀 கவனிக்க வேண்டியவை
Track the volume ramp-up of the newly commissioned dedicated facility in Q2 FY27 and look for signs of demand revival in agrochemical intermediates.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Q1 Net Profit at 29.1 Cr, Down 13% YoY but Up 129% QoQ
Excel Industries reported a mixed performance for Q1 FY27, with revenue from operations at 293.73 Cr, a 5.1% decline compared to 309.47 Cr in Q1 FY26. Net profit followed a similar YoY trend, falling 13.3% to 29.11 Cr from 33.56 Cr. However, the company showed a significant sequential recovery, with net profit more than doubling from 12.71 Cr in Q4 FY26. The company maintains a strong balance sheet with a debt-to-equity ratio of 0.01 and a net worth of 1,221 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its first-quarter results for FY27, showing a significant sequential profit rebound despite a year-on-year decline in both revenue and profit.
ஏன் இது முக்கியம்The results indicate a potential bottoming out of the margin pressure seen in FY26, although the agrochemical sector remains sensitive to monsoon patterns and export headwinds.
📅 குறுகிய காலம்The strong sequential profit growth may provide short-term support to the stock price, though the YoY decline reflects ongoing industry challenges.
📈 நீண்ட காலம்The company's strategy to expand into non-agro specialty chemicals and biocides is critical for long-term structural growth and reducing dependence on cyclical agrochemical markets.
⚠ அபாய எச்சரிக்கைகள்
Cyclicality of the agrochemical segment
Sensitivity to monsoon patterns
Export market headwinds
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the sequential margin recovery and the execution of the planned 35-40 Cr investment in non-agro specialty chemicals to reduce cyclicality.
1265 MTPA Specialty Chemical Capacity Addition at Rs 5.05 Cr Investment
Excel Industries is setting up a new 1265 MTPA facility for a specialty chemical at its Lote site, targeting both domestic and international markets. The project involves a modest investment of Rs 5.05 crore, which will be funded entirely through internal accruals. Commissioning and the subsequent product launch are expected by February 2027. While the investment is small at approximately 0.46% of TTM revenue, it aligns with the company's strategy to diversify its portfolio into non-agro specialty chemicals.
உச்சம் நம்பிக்கை
என்ன மாறியதுExcel Industries is expanding its product basket by setting up a dedicated 1265 MTPA manufacturing line for a new specialty chemical at its Lote facility.
ஏன் இது முக்கியம்This move is part of the company's strategy to reduce dependence on the cyclical agrochemical sector, which is currently sensitive to monsoon patterns and export headwinds.
Proposed Capacity: 1265 MTPAInvestment Value: Rs 5.05 croreInvestment vs TTM Revenue: 0.46%Expected Launch Date: பிப்ரவரி 2027TTM வருவாய்: Rs 1094 கோடி
📅 குறுகிய காலம்The announcement is unlikely to trigger significant price movement given the small size of the investment relative to the company's Rs 1145 Cr market cap.
📈 நீண்ட காலம்While the current investment is small, it represents a continued shift toward non-agro specialty chemicals, which could lead to more stable margins over the long term.
⚠ அபாய எச்சரிக்கைகள்
Execution risk regarding the February 2027 commissioning timeline
Market acceptance risk for the new product
👀 கவனிக்க வேண்டியவை
Investors should monitor the commissioning timeline in early 2027 and look for management commentary on the margin profile of this new specialty chemical in future earnings calls.
Excel Industries has successfully commissioned a dedicated manufacturing facility for a 5-year specialty chemical supply agreement with a leading Indian firm. The project involved a Rs 40 Cr capex and was completed on schedule on July 23, 2026. The contract is expected to generate Rs 35-40 Cr in annual income net of raw material costs, which is highly significant given the company's TTM PAT of Rs 75 Cr. This commissioning marks a strategic shift towards non-agro specialty chemicals and contract manufacturing.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from the construction phase to the production phase for a major long-term supply contract signed in late 2025.
ஏன் இது முக்கியம்The projected annual income (net of RM) of ~Rs 37.5 Cr (midpoint) represents nearly 50% of the company's TTM Net Profit, suggesting a potential for significant earnings accretion and margin improvement.
Estimated Capex: Rs 40 கோடிAnnual Income (Net of RM): Rs 35-40 CrContract Duration: 5 yearsCapex vs Net Worth: 3.3%Income (Net of RM) vs TTM PAT: 50%
📅 குறுகிய காலம்The timely completion of the project is a positive execution signal that may support the stock price in the coming weeks as the market factors in the new revenue stream.
📈 நீண்ட காலம்This project establishes a base for the company's contract manufacturing vertical, potentially leading to a re-rating if it successfully diversifies away from the volatile agrochemical sector.
⚠ அபாய எச்சரிக்கைகள்
Customer concentration risk due to a dedicated facility for a single client
Execution risk in ramping up production to full capacity
👀 கவனிக்க வேண்டியவை
Watch for the revenue and margin ramp-up in the September 2026 quarterly results to confirm the incremental contribution of this contract to the bottom line.
Excel Industries has successfully commissioned a dedicated manufacturing facility for a specialty chemicals contract as of July 23, 2026. The project involved a capital expenditure of approximately Rs 40 Cr, which is roughly 3.3% of the company's net worth. This facility is tied to a long-term contract expected to generate an annual income (net of raw material costs) of Rs 35-40 Cr. This move aligns with the company's strategy to expand its non-agro specialty chemicals portfolio and reduce dependence on cyclical agrochemical markets.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from the investment/construction phase to the operational phase for a major contract manufacturing project.
ஏன் இது முக்கியம்The expected annual income (net of RM) of ~Rs 35-40 Cr is significant compared to the TTM PAT of Rs 75 Cr, potentially providing a high-margin revenue stream and diversifying the business away from agrochemicals.
Estimated Capex: Rs 40 கோடிExpected Annual Income (Net of RM): Rs 35-40 CrCapex vs Net Worth: ~3.3%Income vs TTM PAT: ~47-53%Completion Date: 23rd ஜூலை 2026
📅 குறுகிய காலம்Positive sentiment is expected as the project was completed within the timeline, signaling strong execution capabilities.
📈 நீண்ட காலம்This expansion supports a structural shift toward high-value specialty chemicals, which could improve the company's overall operating margins (currently 10.1%) and reduce earnings volatility.
⚠ அபாய எச்சரிக்கைகள்
Client concentration risk for the dedicated facility
Execution risk in achieving the projected income levels
👀 கவனிக்க வேண்டியவை
Monitor the revenue ramp-up and margin contribution from this facility in the Q2 and Q3 FY27 results to validate the projected Rs 35-40 Cr annual income.
Excel Industries Reports 12% Revenue Growth in FY26; Declares ₹13.75 Final Dividend
Excel Industries reported a steady performance for FY26 with revenues reaching ₹1,094 crores, up 11.8% year-on-year, despite a challenging first half for the agrochemical sector. The company's EBITDA for the year stood at ₹112 crores with a 10.1% margin, while the balance sheet remains strong with zero long-term debt. Management highlighted the operationalization of a 2,530 TPA biocide capacity and a new contract manufacturing line expected by July 2026. A final dividend of ₹13.75 per share was declared, reflecting a 275% payout on face value.
முக்கிய அம்சங்கள்
FY26 net operating revenue grew 11.8% YoY to ₹1,094 crores with a PAT of ₹73 croresDeclared a final dividend of ₹13.75 per equity share, representing 275% of the face valueNew capacity of 2,530 TPA for biocides became operational in H2 FY26 to drive future volumesMaintains a strong financial position with zero long-term debt and a net cash surplusDedicated contract manufacturing line for a major MNC agreement is on track for July 2026 commissioning
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful ramp-up of the new contract manufacturing line in July 2026 and the impact of monsoon patterns on agrochemical demand. While the dividend provides a yield cushion, the company's ability to improve EBITDA margins beyond the current 10% range is critical for long-term re-rating.
Excel Industries FY26 Revenue Up 12% to ₹1,094 Cr; PAT Declines 12% on Margin Pressure
Excel Industries reported a 12% YoY growth in standalone revenue to ₹1,094 Cr for FY26, driven by improved demand for agrochemical intermediates and biocides. However, full-year PAT declined by 12% to ₹73 Cr as adjusted EBITDA margins contracted from 12.3% to 10.1% due to rising input material costs. The Q4 performance showed recovery with revenue and PAT growing 13% and 12% respectively. The company operationalized a new R&D center and remains focused on expanding its biocide portfolio and contract manufacturing projects.
முக்கிய அம்சங்கள்
Standalone revenue for FY26 grew 11.88% to ₹1,094.2 Cr, while Q4 revenue rose 13.4% to ₹281.1 Cr.Full-year PAT decreased by 12.1% to ₹73.4 Cr as margins were impacted by higher raw material costs.Adjusted EBITDA margins for FY26 contracted to 10.1% from 12.3% in the previous fiscal year.Export revenue grew by 26% YoY, contributing 20% (₹223 Cr) to the total revenue in FY26.Operationalized a new Corporate R&D Center at Rabale, Navi Mumbai, to support long-term product development.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to sustain the Q4 recovery and manage raw material volatility, especially with El Niño risks. The growth in the biocide segment and progress in contract manufacturing remain key long-term triggers.
Excel Industries Recommends Final Dividend of Rs 13.75 Per Share for FY 2025-26
Excel Industries Limited has announced a final dividend of Rs 13.75 per equity share for the financial year ended March 31, 2026. This dividend represents a 275% payout on the face value of Rs 5 per share. The recommendation is subject to shareholder approval at the upcoming Annual General Meeting (AGM). Additionally, the company reported its audited financial results for the full year with an unmodified auditor's opinion from Price Waterhouse.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs 13.75 per equity share (275% of face value of Rs 5)Board approved audited standalone and consolidated financial results for the year ended March 31, 2026Dividend to be paid within 30 days of shareholder approval at the ensuing AGMStatutory auditors issued an unmodified opinion on the financial results for FY 2025-26
👀 கவனிக்க வேண்டியவை
Investors should monitor the announcement of the AGM date and record date to ensure eligibility for the Rs 13.75 per share dividend. The stock remains a watch for those seeking dividend yield in the chemicals and biotech sector.
Excel Industries Board Meeting on May 22, 2026, to Consider FY26 Results and Dividend
Excel Industries Limited has scheduled a Board of Directors meeting for May 22, 2026, to approve the audited financial results for the fiscal year ended March 31, 2026. The board will also evaluate and potentially recommend a dividend for the financial year 2025-26. In compliance with SEBI insider trading regulations, the trading window for insiders will remain closed until May 24, 2026, and will reopen on May 25, 2026. This meeting is a standard regulatory requirement for annual financial reporting and corporate distribution decisions.
முக்கிய அம்சங்கள்
Board meeting scheduled for May 22, 2026, to approve audited FY26 financial results.Potential dividend recommendation for the financial year 2025-26 will be considered.Trading window for designated persons remains closed until May 24, 2026.The announcement follows SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the May 22 meeting for the company's full-year performance and dividend yield. No immediate action is necessary until the financial data and dividend payout details are released.
Excel Industries Corrects Q2 FY26 EPS from 41.90 to 14.90 Following NSE Query
Excel Industries Limited has issued a clarification regarding a reporting error in its financial results for the quarter ended September 30, 2025. The company admitted that the Earnings Per Share (EPS) was incorrectly stated as 41.90 in the XBRL filing due to an inadvertent error. The actual EPS for the period is 14.90, which is significantly lower than the figure previously recorded in the exchange's digital format. The company has now submitted the corrected XBRL filing to the National Stock Exchange.
முக்கிய அம்சங்கள்
Standalone EPS for the quarter ended September 30, 2025, revised from 41.90 to 14.90Clarification issued in response to a discrepancy notice from the National Stock Exchange (NSE)The error was attributed to an inadvertent mistake during the XBRL filing processRevised XBRL data has been uploaded to the NEAPS portal to reflect the correct financial metrics
👀 கவனிக்க வேண்டியவை
Investors should update their financial models to reflect the corrected EPS of 14.90 for the September 2025 quarter. While this is a clerical correction, the significant difference in the figures warrants a more cautious look at the company's internal reporting controls.
Excel Industries Q3 Net Profit Rises 31% YoY to ₹8.40 Cr; Revenue Up 19%
Excel Industries reported a 19% YoY growth in revenue from operations to ₹233.45 crore for the quarter ended December 31, 2025. Net profit for the quarter increased by 31.3% YoY to ₹8.40 crore, showing a recovery from the previous year's quarterly performance. However, for the nine-month period, net profit declined by 15.8% YoY to ₹60.69 crore, indicating some margin pressure earlier in the fiscal year. The company has also reorganized its reporting into a single 'Chemicals' segment and made a one-time provision of ₹1.15 crore for gratuity due to new Labour Codes.
முக்கிய அம்சங்கள்
Quarterly Revenue from operations grew 18.8% YoY to ₹233.45 crore from ₹196.41 crore.Net Profit for Q3 FY26 stood at ₹8.40 crore, up from ₹6.40 crore in the same period last year.Nine-month (9M) Revenue increased to ₹813.12 crore compared to ₹730.23 crore in the previous year.The company transitioned to a single operating and reportable segment named 'Chemicals' for better strategic focus.An incremental provision of ₹115.42 lakhs was made for Gratuity following the notification of new Government Labour Codes.
👀 கவனிக்க வேண்டியவை
The quarterly recovery in profit and revenue growth is a positive signal, though the year-to-date profit decline warrants a cautious outlook on overall margin stability. Investors should monitor if the new single-segment focus improves operational efficiency in upcoming quarters.
Excel Industries Q3 FY26 Revenue Rises 19% to ₹233 Cr; PAT Up 31% YoY
Excel Industries reported a strong Q3 FY26 with revenue growing 19% YoY to ₹233 crore, driven by improved demand in performance solutions and better price realizations. While quarterly PAT rose 31% to ₹8 crore, the 9-month performance shows a cumulative decline in profitability with 9M PAT down 16% YoY to ₹61 crore. The company is planning a significant capital expenditure of ₹200-300 crore over the next three years for capacity expansion and technology upgrades. Export contributions remain steady, accounting for 27% of quarterly revenue.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue grew 19% YoY to ₹233 Cr, while Adjusted EBITDA rose 39% to ₹17 Cr.9M FY26 Revenue increased 11% to ₹813 Cr, though PAT declined 16% to ₹61 Cr compared to the previous year.Planned Capex of ₹200-300 Cr over the next 3 years for plant upgrades, product innovation, and capacity expansion.Adjusted EBITDA margin for Q3 FY26 improved by 100bps YoY to 7.3% due to favorable product mix.Export revenue contributed 27% to the total revenue in Q3 FY26, up from 22.3% for the 9-month period.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the ₹200-300 crore capex plan and the recovery in 9-month profitability margins. The strong quarterly growth in performance solutions and biocides suggests a positive turnaround in demand that needs to be sustained.
Excel Industries Approves Unaudited Financial Results for Q3 FY2025-26
Excel Industries Limited has officially approved its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors met on February 3, 2026, for over four and a half hours to review and finalize the performance metrics. The submission includes the statutory Limited Review Report, ensuring regulatory compliance under SEBI guidelines. While the cover letter does not disclose specific profit figures, it confirms the completion of the audit committee's review process.
முக்கிய அம்சங்கள்
Board approved financial results for the quarter and nine months ended December 31, 2025.The Board meeting lasted approximately 4 hours and 40 minutes, concluding at 06:40 p.m.Results were reviewed and recommended by the Audit Committee prior to Board approval.The filing includes the Limited Review Report issued by the company's statutory auditors.The announcement covers both Chemicals and Environment & Biotech divisions.
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed financial tables attached to the full report to evaluate margin performance in the chemical segment. Compare the year-on-year growth for the nine-month period ending December 2025 to assess the company's recovery or growth trajectory.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
